Tirzepatide
Also known as Mounjaro · Zepbound · LY3298176
New
Reconstitution & dosing guide
5 mg · 10 mg · 15 mg · 20 mg · 30 mg · 40 mg · 50 mg · 60 mg · 100 mg vial sizes — research phases, recon steps, and a live unit calculator.
Available sizes & price
Catalog only10mg x 10 vials
Tirzepatide (T10) · Not in current stock
$75 / vial
100mg x 10 vials
Tirzepatide (T100) · Not in current stock
$435 / vial
15mg x 10 vials
Tirzepatide (T15) · Not in current stock
$99 / vial
20mg x 10 vials
Tirzepatide (T20) · Not in current stock
$120 / vial
30mg x 10 vials
Tirzepatide (T30) · Not in current stock
$165 / vial
40mg x 10 vials
Tirzepatide (T40) · Not in current stock
$200 / vial
5mg x 10 vials
Tirzepatide (T5) · Not in current stock
$40 / vial
50mg x 10 vials
Tirzepatide (T50) · Not in current stock
$235 / vial
60mg x 10 vials
Tirzepatide (T60) · Not in current stock
$270 / vial
Prices per vial · Research use only · Not medical advice.
Dual GIP/GLP-1 receptor agonist with strong clinical weight-loss and glycemic outcomes.
How to picture it
Same "fed message" idea as GLP-1 drugs, but tirzepatide knocks on two doors: GLP-1 and GIP receptors. Two gut-hormone pathways for appetite, insulin-response support, and metabolic control — a dual key instead of a single key. The educational feature is broader coverage of the post-meal gut-hormone conversation, not just one incretin channel.
Research focus & benefits
- Dual GIP/GLP-1 metabolic and weight research
- Strong clinical literature on body weight and glycemia
- Appetite and insulin-response pathway interest
Benefits describe research interest and pathway rationale — not guaranteed outcomes or medical advice. Research use only.
Overview
Tirzepatide is a dual incretin agonist approved for type 2 diabetes (Mounjaro) and weight management (Zepbound). In trials it produced larger average weight reductions than semaglutide at studied doses, making it a top biohacking/metabolic discussion compound.
Mechanism
Agonizes both GIP and GLP-1 receptors, enhancing insulin response, reducing appetite, and improving metabolic markers.
Research uses
- Type 2 diabetes
- Obesity
- Obstructive sleep apnea (related approvals/contexts)
- Metabolic disease research
Research dosing notes
Weekly titration schedule under prescription labeling. Do not combine casually with other incretins.
Half-life / kinetics
~5 days (weekly dosing)
Common research routes
Reported considerations
- GI upset (nausea, diarrhea, constipation)
- Injection-site reactions
- Gallbladder risk
- Muscle loss without training stimulus
Contraindications / cautions
- MTC/MEN2 history
- Pregnancy
- Severe GI disease
Common research stacks
- Resistance training
- High protein
- Medical monitoring of lean mass
Legal / access note
Prescription-only approved medicines exist. Gray-market research vials are not equivalent.